Skip to content

Polarized Reflectance Spectroscopy for Oral Lesions

Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01604759
Acronym
PolProbe
Enrollment
40
Registered
2012-05-24
Start date
2011-12-31
Completion date
2015-12-31
Last updated
2017-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Cancer

Keywords

Mouth Neoplasms, Mouth Diseases

Brief summary

In this study the investigators are conducting research to determine whether a new optical device using polarization reflectance spectroscopy can help doctors or dentists identify abnormalities in the mouth that require follow-up. To establish this, measurements are needed from a large number of individuals with different abnormalities in their mouth. The investigators believe the proposed approach has potential to improve and enable mass screening for precancerous and early cancers of the oral cavity by improving the predictive value of oral cavity exams, particularly for less experienced practitioners. The information from this study will be compared to results from the pathology report of the tissue taken from your mouth. Hypothesis: 1. Polarized reflectance spectroscopy can distinguish high-risk oral lesion from normal and reactive oral lesions. 2. Polarized reflectance spectroscopy can capture low-grade oral lesions that have characteristics associated with a high risk of progression to cancer.

Detailed description

The clinician will place a fiber-optic probe designed to measure the polarized reflectance spectra over the visible optical region on a site of interest in the subject's mouth, including lesional mucosa, normal adjacent and contralateral mucosa. The site for placement of the probe will be determined by the examiner, an experienced Oral Pathologist. The probe examination will take no more than 15 minutes in addition to the subject's appointment time for their routine visits. A 4um unstained tissue section from surgery or biopsy, part of their scheduled care, will be requested for quantitative histological analysis. The morphometric parameters obtained from polarized reflectance measurements will be compared with the histology and quantitative pathology (nuclear phenotype score) from the tissue sections from the lesion. The collected spectra data from normal looking areas from adjacent normal looking mucosa and contralateral mucosa will be used to determine patient to patient variation in the polarized reflectance of oral mucosa.

Interventions

DEVICEPolarized Reflectance Spectroscopy System

Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.

Sponsors

M.D. Anderson Cancer Center
CollaboratorOTHER
University of Texas at Austin
CollaboratorOTHER
British Columbia Cancer Agency
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* You attend the Dental Department at the British Columbia Cancer Agency * You have an abnormal lesion in the mouth * You fully understand the study and give your informed consent to participate as demonstrated by signing this consent form

Exclusion criteria

* You are under the age of 18 years.

Design outcomes

Primary

MeasureTime frameDescription
To use the spectroscopic data collected to create a model for normal, dysplastic and cancerous tissue.2 yearsThe goals of the statistical analysis will be to determine an appropriate model for predicting whether the lesion is normal or abnormal (dysplasia or carcinoma) based on spectroscopic characteristics. The investigators will estimate sensitivity and specificity of the predictions made by the model and compare this to sensitivity and specificity of standard white light clinical examination currently used in clinical practice.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026